Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy

被引:21
作者
Kellie, SJ [1 ]
Chaku, J
Lockwood, LR
O'Regan, P
Waters, KD
Wong, CKF
机构
[1] Univ Sydney, Dept Paediat, Sydney, NSW 2006, Australia
[2] Childrens Hosp Westmead, Dept Oncol, Sydney, NSW, Australia
[3] Royal Childrens Hosp, Dept Haematol & Oncol, Brisbane, Qld, Australia
[4] Royal Childrens Hosp, Dept Haematol & Oncol, Melbourne, Vic, Australia
[5] Childrens Hosp Westmead, Dept Radiol, Sydney, NSW, Australia
关键词
medulloblastoma; methotrexate; leukoencephalopathy; radiation therapy;
D O I
10.1016/j.ejca.2005.02.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-dose methotrexate (HDMTX) is used increasingly to treat children with central nervous system (CNS) tumours. Although the neuro-imaging features of leukoencephalopathy associated with systemic or intrathecal methotrexate administered after cranial radiation have been well described, the extent to which the sequencing of HDMTX prior to cranial radiation in infants and children predisposes to late neuroradiological features of leukoencephalopathy is unknown. This report describes the National Cancer Institute (NCI) toxicity grade of leukoencephalopathy based on magnetic resonance imaging (MRI) findings in all patients who survived 4 or more years after treatment on an earlier phase 11 study. These patients, with newly diagnosed CNS embryonal tumours, were in the age range 3.5-14.2 years (median 6.9 years) at diagnosis, and received four courses of pre-irradiation combination chemotherapy, including HDMTX 8 g/m(2). Following completion of the 'up-front' phase 11 study, all patients received conventionally fractionated whole brain doses of 36-50.4 Gy. The radiation dose and treatment volumes were determined individually according to the primary tumour location and results of extent of disease evaluations. The most recent MRI brain scans, obtained 4.0-10.5 years (median 6.5 years) after radiation therapy and comprising a minimum of T1, T1 following gadolinium and T2 sequences, were reviewed centrally to assess the neuroradiological grade of leukoencephalopathy, based on the NO Common Terminology Criteria for Adverse Events, v3.0. Grade I changes (mild increase in subarachnoid space, and/or mild ventriculomegaly, and/or small/focal T2 hyperintensities) were evident in 8 of the 12 patients and grade 11 changes (moderate increase in subarachnoid space and/or moderate ventriculomegaly, and/or focal T2 hyperintensities extending to the centrum ovale) were found in the remaining 4. In conclusion, treatment with multiple courses of HDMTX prior to 36-50.4 Gy cranial radiation did not result in moderate to severe MRI features of leukoencephalopathy. Future studies in paediatric neuro-oncology patients, involving HDMTX combined with prospective neuropsychological evaluations appear justified. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1588 / 1596
页数:9
相关论文
共 51 条
[1]  
ALLEN JC, 1980, CANCER TREAT REP, V64, P1261
[2]   PRERADIATION HIGH-DOSE INTRAVENOUS METHOTREXATE WITH LEUCOVORIN RESCUE FOR UNTREATED PRIMARY CHILDHOOD BRAIN-TUMORS [J].
ALLEN, JC ;
WALKER, R ;
ROSEN, G .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :649-653
[3]   LEUKOENCEPHALOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS METHOTREXATE CHEMOTHERAPY - QUANTITATIVE ASSESSMENT OF WHITE MATTER ATTENUATION USING COMPUTED TOMOGRAPHY [J].
ALLEN, JC ;
THALER, HT ;
DECK, MDF ;
ROTTENBERG, DA .
NEURORADIOLOGY, 1978, 16 :44-47
[4]  
BALL WS, 1992, AM J NEURORADIOL, V13, P761
[5]   BRAIN-DAMAGE AFTER TREATMENT FOR ACUTE LYMPHOBLASTIC-LEUKEMIA - A REPORT ON 34 PATIENTS WITH SPECIAL REGARD TO MRI FINDINGS [J].
BITI, GP ;
MAGRINI, SM ;
VILLARI, N ;
CARAMELLA, D ;
GUAZZELLI, G ;
ROSI, A ;
LIPPI, A .
ACTA ONCOLOGICA, 1989, 28 (02) :253-256
[6]   High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series [J].
Blay, JY ;
Conroy, T ;
Chevreau, C ;
Thyss, A ;
Quesnel, N ;
Eghbali, H ;
Bouabdallah, R ;
Coiffier, B ;
Wagner, JP ;
Le Mevel, A ;
Dramais-Marcel, D ;
Baumelou, E ;
Chauvin, F ;
Biron, P .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :864-871
[7]  
BLEYER WA, 1981, CANCER TREAT REP, V65, P89
[8]   LEUKOENCEPHALOPATHY DETECTABLE BY MAGNETIC-RESONANCE-IMAGING - MUCH ADO ABOUT NOTHING [J].
BLEYER, WA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (04) :1251-1252
[9]  
Bleyer WA, 1998, MED PEDIATR ONCOL, P10
[10]  
BURGER PC, 1979, CANCER, V44, P1256, DOI 10.1002/1097-0142(197910)44:4<1256::AID-CNCR2820440415>3.0.CO